iScience (Oct 2023)

Targeting adrenergic receptors to mitigate invariant natural killer T cells-induced acute liver injury

  • Michelangelo Bauwelz Gonzatti,
  • Beatriz Marton Freire,
  • Maísa Mota Antunes,
  • Gustavo Batista de Menezes,
  • Jhimmy Talbot,
  • Jean Pierre Schatzmann Peron,
  • Alexandre Salgado Basso,
  • Alexandre Castro Keller

Journal volume & issue
Vol. 26, no. 10
p. 107947

Abstract

Read online

Summary: Invariant Natural Killer T (iNKT) cell activation by α-galactosylceramide (αGC) potentiates cytotoxic immune responses against tumors. However, αGC-induced liver injury is a limiting factor for iNKT-based immunotherapy. Although adrenergic receptor stimulation is an important immunosuppressive signal that curbs tissue damage induced by inflammation, its effect on the antitumor activity of invariant Natural Killer T (iNKT) cells remains unclear. We use mouse models and pharmacological tools to show that the stimulation of the sympathetic nervous system (SNS) inhibits αGC-induced liver injury without impairing iNKT cells’ antitumoral functions. Mechanistically, SNS stimulation prevents the collateral effect of TNF-α production by iNKT cells and neutrophil accumulation in hepatic parenchyma. Our results suggest that the modulation of the adrenergic signaling can be a complementary approach to αGC-based immunotherapy to mitigate iNKT-induced liver injury without compromising its antitumoral activity.

Keywords